Agios Pharmaceuticals, Inc.
AGIO
$27.42
-$0.07-0.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.88M | 12.46M | 8.73M | 10.73M | 8.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.88M | 12.46M | 8.73M | 10.73M | 8.96M |
| Cost of Revenue | 88.48M | 93.64M | 73.83M | 84.07M | 73.24M |
| Gross Profit | -75.60M | -81.19M | -65.10M | -73.34M | -64.27M |
| SG&A Expenses | 41.27M | 45.87M | 41.53M | 51.70M | 38.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.75M | 139.51M | 115.36M | 135.77M | 111.78M |
| Operating Income | -116.87M | -127.06M | -106.63M | -125.04M | -102.81M |
| Income Before Tax | -103.43M | -112.02M | -89.29M | -105.40M | 1.00B |
| Income Tax Expenses | -- | -- | -- | -8.88M | 53.12M |
| Earnings from Continuing Operations | -103.43M | -112.02M | -89.29M | -96.52M | 947.92M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.43M | -112.02M | -89.29M | -96.52M | 947.92M |
| EBIT | -116.87M | -127.06M | -106.63M | -125.04M | -102.81M |
| EBITDA | -115.50M | -125.80M | -105.35M | -123.67M | -101.47M |
| EPS Basic | -1.78 | -1.93 | -1.55 | -1.69 | 16.65 |
| Normalized Basic EPS | -1.11 | -1.21 | -0.97 | -1.15 | -0.97 |
| EPS Diluted | -1.78 | -1.93 | -1.55 | -1.69 | 16.22 |
| Normalized Diluted EPS | -1.11 | -1.21 | -0.97 | -1.15 | -0.94 |
| Average Basic Shares Outstanding | 58.14M | 57.93M | 57.46M | 57.10M | 56.94M |
| Average Diluted Shares Outstanding | 58.14M | 57.93M | 57.46M | 57.10M | 58.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |